Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Severe bilateral conjunctival inflammation following rituximab therapy succesfully treated with topical tacrolimus

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Presented Poster Session: Dry Eye and Inflammation

Session Date/Time: Monday 07/09/2015 | 15:00-16:30

Paper Time: 15:50

Venue: Poster Village: Pod 3

First Author: : S.Martin-Nalda SPAIN

Co Author(s): :    M. Calatayud   J. Puig-Galy   L. Bisbe   L. De Nicola   A. Calvo   J. Rigo

Abstract Details


To describe two cases of severe bilateral chronic papillary conjunctivitis following rituximab therapy for lymphoma successfully treated with topical tacrolimus


Cornea and ocular surface unit, Vall d Hebron Hospitals, Barcelona, Spain


Two patients were referred to our hospital because of severe bilateral chronic papillary conjunctivitis following rituximab treatment for non–Hodgkin´s lymphoma resistant to topical steroids.


After a few weeks of rituximab therapy the patients had severe conjunctival hyperemia resistant to topical treatment included steroids. A few months after cessation of rituximab treatment the bilateral conjunctivitis didn´t improve. At that moment we decided to start with topical tacrolimus and in a few days the improvement was dramatic.


Adverse effects of rituximab (anti-CD20 monoclonal antibody) such as fever, hypotension, tachycardia and urticaria have been described but to our knowledge chronic conjunctivitis without resolution after discontinuation of the treatment has not been described before. We decided to start with topical tacrolimus not only for its effect as immunosuppressive and immunomodulatory agent but also because the conjunctival inflammation was refractory to conventional treatment with steroids. Topical tacrolimus has been shown effective in treating severe conjunctival inflammation following rituximab therapy.

Financial Interest:


Back to previous